Courtney Flaherty

Courtney Flaherty joined OncLive as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: cflaherty@onclive.com

Articles

Dr Nowakowski on the FDA Approval of Brentuximab Vedotin for R/R LBCL

March 13th 2025

Grzegorz S. Nowakowsi, MD, discusses the unique mechanism of action of brentuximab vedotin plus lenalidomide and rituximab in ​relapsed/refractory LBCL.

Fixed-Duration Mosunetuzumab Demonstrates Preliminary Activity in BTK Inhibitor–Exposed R/R MCL

March 13th 2025

Single-agent mosunetuzumab generated response rates in patients with relapsed/refractory MCL who previously received a BTK inhibitor.

Dr DeAngelo on the Efficacy of Avapritinib in Advanced Systemic Mastocytosis

March 13th 2025

Daniel J. DeAngelo, MD, PhD, discusses the clinical implications of findings from the PATHFINDER trial of avapritinib in advanced ​​systemic mastocytosis.

Maintenance OSE2101 Plus FOLFIRI Meets Primary OS End Point in Advanced/Metastatic PDAC

March 12th 2025

Maintenance treatment with OSE2101 plus FOLFIRI after FOLFIRINOX induction chemotherapy displayed positive topline results in advanced/metastatic PDAC.

Imetelstat Earns EU Approval for Transfusion-Dependent Anemia in Lower-Risk MDS

March 12th 2025

The European Commission has approved imetelstat for the treatment of patients with transfusion-dependent anemia in lower-risk myelodysplastic syndrome.

SAR444200 Demonstrates Safety, Signals of Clinical Activity in Advanced GPC3+ HCC, Other Solid Tumors

March 11th 2025

SAR444200-mediated targeting of GPC3-expressing solid tumors was safe and showed early signs of antitumor activity in a phase 1/2 study.

Cema-Cel Induces CRs and Has Manageable Safety Profile in CD19 CAR T-Cell Therapy–Naive R/R LBCL

March 11th 2025

Cema-cel generated CRs, most of which were durable, among patients with relapsed/refractory LBCL who were naive to anti-CD19 CAR T-cell therapy.

Dr Davila on ​the Clinical Implications of Tumor Driver and Immune Escape Research in LBCL

March 10th 2025

Marco Davila, MD, PhD, discusses research investigating ways to combat immune escape mechanisms in LBCL treated with CD19-directed CAR T-cell therapy.

Dr Ruella on the Importance of Clinical Trial and Treatment Accessibility for Myeloma

March 10th 2025

Marco Ruella, MD, discusses ways to develop accessible cancer treatments to more greatly benefit diverse populations of patients with multiple myeloma.

Neratinib Generates CNS Responses Across HER2+ Breast Cancer Brain Metastases Subgroups

March 10th 2025

Neratinib-containing combinations are consistently effective across CNS end points in patients with HER2-positive breast cancer brain metastases.

Abemaciclib Delivers Consistent Benefit in High-Risk, Early Breast Cancer Regardless of Dose Reductions

March 8th 2025

Patients with high-risk, early breast cancer receiving adjuvant abemaciclib maintained benefit with the agent regardless of dose modification.

Same-Day Dosing of Eflapegrastim and Chemotherapy Is Safe, Reduces Duration of Severe Neutropenia in Early-Stage Breast Cancer

March 8th 2025

Same-day administration of eflapegrastim and cycle 1 of chemotherapy reduced the mean duration of severe neutropenia in early-stage breast cancer.

International Women’s Day Highlights Importance of Female Mentorship for Early-Career Women in Oncology

March 8th 2025

Megan Melody, MD, discusses her journey as an oncologist and the importance of mentorship and a supportive work environment to empower women in the field.

Dr Meattini on Adjuvant Radiotherapy vs Endocrine Therapy in Early Breast Cancer

March 7th 2025

Icro Meattini, ​MD, discusses the benefits of adjuvant radiation therapy vs endocrine therapy in patients with luminal-like early breast cancer.

Dr Uboha on the FDA Approval of First-Line Tislelizumab Plus Chemotherapy for Metastatic ESCC

March 7th 2025

Nataliya Uboha, MD, PhD, discusses how the FDA approval of tislelizumab plus chemotherapy​ addresses unmet needs for patients with metastatic ESCC.

Updated Data Further Support KEYNOTE-522 Regimen as SOC in High-Risk, Early-Stage TNBC

March 7th 2025

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab provides meaningful OS benefits in high-risk, early-stage TNBC.

Imulnestrant Plus Abemaciclib Extends PFS Over SOC in ER+/HER2– Advanced Breast Cancer

March 7th 2025

Imlunestrant generated PFS benefit with or without abemaciclib for select patients with ER-positive, HER2-negative advanced breast cancer.

Liso-Cel Prolongs Responses, PFS, and OS in Pretreated, High-Risk, R/R CLL

March 6th 2025

Treatment with liso-cel induced long-term CR/CRi rates and high uMRD rates in patients with CLL/SLL following progression on BTK inhibition and venetoclax.

177Lu-edotreotide Radiopharmaceutical Therapy Prolongs PFS vs Everolimus in SSTR+ GEP-NETs

March 6th 2025

Treatment with 177Lu-edotreotide significantly improved PFS and numerically increased OS vs SOC everolimus in grade 1 or 2 SSTR-positive GEP-NETs.

Olverembatinib Plus Chemo Receives Breakthrough Therapy Designation in China for Newly Diagnosed Ph+ ALL

March 6th 2025

First-line olverembatinib plus low-intensity chemotherapy has received breakthrough therapy designation in China for patients with Ph-positive ALL.

NEXT PAGE
PREVIOUS PAGE
x